-8.43%
27.06%
70.81%
46.47%
89.85%
-46.46%
-16.96%
AI Spotlight on ANGO
Company Description
AngioDynamics, Inc.designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally.The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors.
It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits.In addition, the company provides endovascular therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency.Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies that are used primarily to deliver short-term drug therapies, such as chemotherapeutic agents and antibiotics, into the central venous system under the BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax names.
It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships.The company was founded in 1988 and is headquartered in Latham, New York.
Market Data
| Last Price | 11.41 |
| Change Percentage | -8.43% |
| Open | 12.4 |
| Previous Close | 12.46 |
| Market Cap ( Millions) | 462 |
| Volume | 1312735 |
| Year High | 13.13 |
| Year Low | 5.26 |
| M A 50 | 9.28 |
| M A 200 | 7.36 |
Financial Ratios
| FCF Yield | -6.87% |
| Dividend Yield | 0.00% |
| ROE | -111.30% |
| Debt / Equity | 2.66% |
| Net Debt / EBIDTA | 340.39% |
| Price To Book | 2.73 |
| Price Earnings Ratio | -2.27 |
| Price To FCF | -14.56 |
| Price To sales | 1.76 |
| EV / EBITDA | -31.53 |
News
- Jan -31 - ANGO Stock Looks Promising on New Ischemia Study for Auryon System
- Jan -16 - AngioDynamics: Improving Financial Performance And Good Clinical Data Reinvigorate The Shares
- Jan -09 - AngioDynamics price target raised to $15 from $12 at Canaccord
- Jan -09 - AngioDynamics Stock Up on Q2 Earnings Beat, Gross Margin Declines
- Jan -08 - AngioDynamics: A Surgical Approach To Market Growth
- Jan -08 - AngioDynamics, Inc. (ANGO) Q2 2025 Earnings Call Transcript
- Jan -08 - AngioDynamics (ANGO) Reports Q2 Loss, Tops Revenue Estimates
- Dec -10 - ANGO Stock Up Post FDA Nod for Prostate Tissue Ablation With NanoKnife
- Dec -10 - Strength Seen in AngioDynamics (ANGO): Can Its 23.3% Jump Turn into More Strength?
- Nov -01 - Wall Street Analysts Believe AngioDynamics (ANGO) Could Rally 94.32%: Here's is How to Trade
- Oct -29 - AngioDynamics Stock Plunges 13.8% in Three Months: What's Next?
- Oct -23 - ANGO Stock Rises Following the Receipt of CPT Category I Code for IRE
- Oct -08 - AngioDynamics (ANGO) Loses -15.86% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
- Oct -04 - AngioDynamics Stock Up on Q1 Earnings Beat, Y/Y Pro-Forma Sales Rise
- Oct -03 - Here's Why You Should Add AngioDynamics Stock to Your Portfolio
- Oct -03 - Why AngioDynamics Stock Is Crashing Today
- Oct -03 - AngioDynamics, Ingevity, Levi Strauss And Other Big Stocks Moving Lower On Thursday
- Oct -03 - AngioDynamics (ANGO) Reports Q1 Loss, Misses Revenue Estimates
- Oct -03 - Top Wall Street Forecasters Revamp AngioDynamics Price Expectations Ahead Of Q1 Earnings
- Sep -30 - New Strong Buy Stocks for September 30th
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Med Device
Expected Growth : 3 %
What the company do ?
The Med Device from AngioDynamics, Inc. is a minimally invasive medical device used to treat peripheral artery disease and other vascular conditions.
Why we expect these perspectives ?
AngioDynamics' Med Device segment growth is driven by increasing demand for minimally invasive procedures, expanding product portfolio through strategic acquisitions, and growing adoption of its NanoKnife ablation system for cancer treatment. Additionally, the company's focus on innovation and R&D investments in emerging technologies such as robotic-assisted surgery and bioelectronic medicine are expected to contribute to its growth.
Segment n°2 -> Med Tech
Expected Growth : 3 %
What the company do ?
Med Tech from AngioDynamics, Inc. is a medical technology company that develops and manufactures innovative medical devices for vascular access, angiography, and radiation oncology.
Why we expect these perspectives ?
AngioDynamics' Med Tech segment growth is driven by increasing demand for minimally invasive procedures, advancements in vascular access technologies, and expansion into new markets. Additionally, the company's focus on innovation, strategic partnerships, and cost-effective solutions contribute to its growth momentum.
Angiodynamics, Inc. Products
| Product Range | What is it ? |
|---|---|
| NanoKnife System | A minimally invasive, irreversible electroporation (IRE) ablation system for the treatment of cancer |
| AngioVac System | A minimally invasive, venous drainage system for the removal of fresh, soft thrombi and emboli from the venous system |
| Solero Microwave Ablation System | A minimally invasive, microwave ablation system for the treatment of soft tissue tumors |
| Maxxum Micro-Dissection System | A minimally invasive, micro-dissection system for the treatment of peripheral artery disease (PAD) |
| Unify RX Access Platform | A minimally invasive, access platform for the treatment of vascular and oncology procedures |
AngioDynamics, Inc.'s Porter Forces
Threat Of Substitutes
AngioDynamics, Inc. operates in a niche market with limited substitutes, but the threat of substitutes is still present due to the ongoing development of new medical technologies.
Bargaining Power Of Customers
AngioDynamics, Inc. has a diverse customer base, which reduces the bargaining power of individual customers. Additionally, the company's products are often critical to medical procedures, making it difficult for customers to negotiate prices.
Bargaining Power Of Suppliers
AngioDynamics, Inc. relies on a few key suppliers for critical components, which gives these suppliers some bargaining power. However, the company's size and diversification efforts mitigate this risk.
Threat Of New Entrants
The medical device industry has high barriers to entry, including regulatory hurdles and significant research and development investments. This limits the threat of new entrants to AngioDynamics, Inc.'s market.
Intensity Of Rivalry
The medical device industry is highly competitive, with several established players competing for market share. AngioDynamics, Inc. must continually innovate and invest in research and development to maintain its competitive position.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 14.58% |
| Debt Cost | 5.63% |
| Equity Weight | 85.42% |
| Equity Cost | 7.30% |
| WACC | 7.06% |
| Leverage | 17.07% |
AngioDynamics, Inc. : Quality Control
AngioDynamics, Inc. passed 4 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| NXGL | NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The … |
| EKSO | Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Europe, the Middle east, Africa, the Asia Pacific, and internationally. The company operates in two segments, … |
| ATRI | Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications in the United States, Canada, Europe, and internationally. Its fluid delivery products … |
| STAA | STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The … |
| BLFS | BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Atrion
A-Score
1-Year Total Return ->
🥈
BioLife Solutions
A-Score
1-Year Total Return ->
🥉
NEXGEL
A-Score
1-Year Total Return ->
4
STAAR Surgical
A-Score
1-Year Total Return ->
5
AngioDynamics
A-Score
1-Year Total Return ->
6
